EA201891351A1 - Вспениваемая композиция галобетазола и способ её применения - Google Patents

Вспениваемая композиция галобетазола и способ её применения

Info

Publication number
EA201891351A1
EA201891351A1 EA201891351A EA201891351A EA201891351A1 EA 201891351 A1 EA201891351 A1 EA 201891351A1 EA 201891351 A EA201891351 A EA 201891351A EA 201891351 A EA201891351 A EA 201891351A EA 201891351 A1 EA201891351 A1 EA 201891351A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
repentable
galobetazol
application
halobetasol
Prior art date
Application number
EA201891351A
Other languages
English (en)
Other versions
EA035300B1 (ru
Inventor
Роберт Т. Готье
Джеймс Д. Хэммер
Original Assignee
Терапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57543101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201891351(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Терапьютикс Инк. filed Critical Терапьютикс Инк.
Publication of EA201891351A1 publication Critical patent/EA201891351A1/ru
Publication of EA035300B1 publication Critical patent/EA035300B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение предлагает композицию и способ лечения различных кожных заболеваний. Композиция выполнена в виде вспениваемой композиции и содержит кортикостероид галобетазол.
EA201891351A 2015-12-15 2016-11-30 Вспениваемая композиция галобетазола (варианты) и способ лечения EA035300B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267749P 2015-12-15 2015-12-15
PCT/IB2016/057227 WO2017103719A1 (en) 2015-12-15 2016-11-30 Halobetasol foam composition and method of use thereof

Publications (2)

Publication Number Publication Date
EA201891351A1 true EA201891351A1 (ru) 2019-01-31
EA035300B1 EA035300B1 (ru) 2020-05-26

Family

ID=57543101

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891351A EA035300B1 (ru) 2015-12-15 2016-11-30 Вспениваемая композиция галобетазола (варианты) и способ лечения

Country Status (14)

Country Link
US (2) US10857159B2 (ru)
EP (1) EP3389631B1 (ru)
JP (1) JP2018538327A (ru)
KR (1) KR20180098300A (ru)
CN (1) CN108601733B (ru)
AU (1) AU2016372789B2 (ru)
BR (1) BR112018012349A2 (ru)
CA (1) CA3008753C (ru)
EA (1) EA035300B1 (ru)
ES (1) ES2770325T3 (ru)
MX (1) MX2018007343A (ru)
PH (1) PH12018501278A1 (ru)
SG (1) SG11201805109YA (ru)
WO (1) WO2017103719A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170340649A1 (en) * 2016-05-30 2017-11-30 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
WO2018020385A1 (en) * 2016-07-27 2018-02-01 Sun Pharmaceutical Industries Limited Touch-free topical spray of halobetasol

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
CN1086580C (zh) * 1998-03-23 2002-06-26 阎丽 一种皮炎止痒软膏
US6479058B1 (en) * 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
IL152486A0 (en) * 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US7186416B2 (en) * 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US20050069499A1 (en) * 2003-09-25 2005-03-31 Moshe Arkin Foamable compositions, processes of preparing same and uses thereof
US9023863B2 (en) * 2006-07-14 2015-05-05 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US20100202978A1 (en) * 2009-02-12 2010-08-12 Gurge Ronald M Foamable benzoyl peroxide compositions for topical administration
MX340791B (es) * 2009-02-25 2016-07-25 Stiefel Res Australia Pty Ltd Composicion de espuma topica.
EP2421521A1 (en) * 2009-04-24 2012-02-29 Janssen Pharmaceuticals, Inc. Stable topical compositions for 1,2,4-thiadiazole derivatives
CN101926765A (zh) * 2009-06-24 2010-12-29 天津金耀集团有限公司 一种糠酸莫米松泡沫剂组合物
US20110212035A1 (en) * 2010-02-26 2011-09-01 Collegium Pharmaceutical, Inc. Emollient foams for treatment of dermatoses
WO2013067271A2 (en) * 2011-11-03 2013-05-10 Precision Dermatology, Inc. Stable dermatological aerosol foams utilizing reactive propellants
EP2804606B1 (en) * 2012-01-19 2017-06-28 Hybrid Medical, LLC Topical therapeutic formulations
US20140079648A1 (en) * 2012-09-14 2014-03-20 Gojo Industries, Inc. Antimicrobial alcoholic foamable compositions
JP6113019B2 (ja) * 2013-08-07 2017-04-12 株式会社ディスコ ウエーハの分割方法
RU2016115481A (ru) * 2013-09-25 2017-10-30 Сан Фармасьютикал Индастриз Лимитед Композиция галобетазола для местного спрея
SG11201805111VA (en) * 2015-12-15 2018-07-30 Therapeutics Inc Corticosteroid containing foam compositions and method of manufacture thereof

Also Published As

Publication number Publication date
BR112018012349A2 (pt) 2018-12-04
CA3008753A1 (en) 2017-06-22
WO2017103719A1 (en) 2017-06-22
EP3389631B1 (en) 2019-11-13
EP3389631A1 (en) 2018-10-24
SG11201805109YA (en) 2018-07-30
US10857159B2 (en) 2020-12-08
US20190365782A1 (en) 2019-12-05
CA3008753C (en) 2023-06-20
JP2018538327A (ja) 2018-12-27
AU2016372789A1 (en) 2018-07-05
EA035300B1 (ru) 2020-05-26
MX2018007343A (es) 2019-03-14
PH12018501278A1 (en) 2019-01-28
CN108601733B (zh) 2021-11-09
CN108601733A (zh) 2018-09-28
ES2770325T3 (es) 2020-07-01
AU2016372789B2 (en) 2021-12-16
US20170165275A1 (en) 2017-06-15
KR20180098300A (ko) 2018-09-03

Similar Documents

Publication Publication Date Title
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DK3474996T3 (da) Tågeapparat og anvendelsesmåde
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CR20190271A (es) Anticuerpos antitau y métodos de uso
DK3377637T3 (da) Sammensætninger til anvendelse i fremgangsmåder til behandling af sår, lidelser og sygdomme i huden
BR112017005002A2 (pt) macropinocitose de anticorpos anti-cd46 humanos e agentes terapêuticos dirigidos contra o câncer.
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EA201791095A1 (ru) Способ лечения рака
IL267673A (en) Broad neutralizing antibodies against hiv-1 and methods of using them
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
ECSP18050575A (es) Composiciones y métodos para disminuir la expresión de tau
IL269390A (en) Preparations and methods for the treatment of parasitic diseases
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
SG11202004680UA (en) Cellular compositions and methods of treatment i
PH12018502154A1 (en) Methods of treating ocular conditions
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
AR101486A1 (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
CO2018008249A2 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b
DK3445362T3 (da) Sammensætning og fremgangsmåde til behandling af stofskiftesygdomme
DK3532072T3 (da) Behandling af glaukom

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KG TM